Once-Daily Dosing of Aminoglycosides

Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.

BACKGROUND People with cystic fibrosis, who are chronically colonised with the organism Pseudomonas aeruginosa, often require multiple courses of intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations. The properties of aminoglycosides suggest that they could be given in higher doses less often. This is an update of a previously published review. OBJECTIVES To as...

Once-daily dosing of gentamicin.

Gentamicin remains one of the most effective and commonly used antimicrobials in the armamentarium of clinicians treating pelvic infections. It continues to reliably cover the aerobic gram-negative rods seen within polymicrobial infections. Available in its generic form, it becomes the low-cost drug of choice in these settings. So why mess with success? As Wiesenfield et al point out in this is...

Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.

The use of higher-dose, extended interval (i.e., once-daily) aminoglycoside regimens to optimize bacterial killing is justified by a pharmacodynamic principle of aminoglycosides, namely concentration-dependent killing, and by the partial attribution of the toxicity of aminoglycosides to prolonged serum concentrations. Numerous in-vitro and animal studies have supported using once-daily aminogly...

Once-daily dosing of nevirapine in HAART.

Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens provide simpler and more easily tolerated treatment alternatives to protease inhibitor-based regimens, potentially improving adherence. Long-term viral suppression relies on adherence to a prescribed antiretroviral treatment regimen. Simplification of dosing schedules has prompted investigations into once-daily dosing regimen...

Once-daily-dosing intramuscular gentamicin in neonates.